FMP
Federated Hermes MDT Mid Cap Growth Fund
FGSKX
NASDAQ
The fund invests primarily in domestic, mid cap common stocks that offer superior growth prospects. Its manager considers mid cap companies to be those of a size similar to companies listed in the Russell Midcap Growth Index. The fund will invest its assets so that at least 80% of its net assets (plus any borrowing for investment purposes) are invested in mid cap investments.
59.11 USD
0.4 (0.677%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
N/A
sector
Financial Services
industry
Asset Management
website
N/A
exchange
NASDAQ
Description
The fund invests primarily in domestic, mid cap common stocks that offer superior growth prospects. Its manager considers mid cap companies to be those of a size similar to companies listed in the Russell Midcap Growth Index. The fund will invest its assets so that at least 80% of its net assets (plus any borrowing for investment purposes) are invested in mid cap investments.
CIK
0000745968
ISIN
US3141725297
CUSIP
314172529
Address
Federated Hermes Equity Funds
Phone
800-341-7400
Country
US
Employee
N/A
IPO Date
Dec 12, 2006
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
FGSKX Financial Summary
CIK
0000745968
Exchange
NASDAQ
Industry
Asset Management
Sector
Financial Services
CUSIP
314172529
ISIN
US3141725297
Country
US
Price
59.11
Beta
1.16
Volume Avg.
0
Market Cap
1.88B
Shares
-
52-Week
39.15-59.03
DCF
0
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-
P/B
-
Website
-
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest FGSKX News
It looks like there's no news available.
